THE Australian Government has awarded $3 million of funding to a new innovative platform tackling respiratory diseases with AI.

Under the Cooperative Research Centres Projects (CRC-P) program, the cash injection will support Diag-Nose.io in developing RhinoMAP, an AI-powered biomarker platform for respiratory disease.

The tool aims to fill a critical gap in how respiratory diseases like asthma, sinusitis and chronic obstructive pulmonary disease (COPD) are monitored and treated, with a recent study showing 40-50% of patients do not achieve adequate treatment response.

RhinoMAP uses protein biomarkers from a nasal fluid sample and combines them with patient-reported data to deliver a real-time picture of airway inflammation, while AI algorithms will enable clinicians to track whether high-cost treatments like biologics are working before current tools would show results.

“New drugs…are expensive and slow to show results, which often lead to clinical uncertainty, lower patient adherence, and sub-optimal use of healthcare resources,” said Diag-Nose.io CEO and co-founder, Eldin Rostom.

“RhinoMAP is like a radar…it reveals whether inflammation is escalating, stable, or resolving to help clinicians course-correct or stay the path with confidence.”

The post AI to help fill gap appeared first on Pharmacy Daily.